About IFFIm
About IFFIm
IFFIm, the International Finance Facility for Immunisation, was founded in 2006 on the idea that private investors and government donors can work together to have a greater, more immediate impact on global health.
IFFIm, the International Finance Facility for Immunisation, was founded in 2006 on the idea that private investors and government donors can work together to have a greater, more immediate impact on global health.
An award-winning socially responsible investment
IFFIm is a role model for socially responsible investing in global development, which faces constant funding challenges and unpredictability. Vaccine Bonds provide investors with a unique opportunity to realise an attractive and secure rate of return and diversify their portfolios while helping save young lives. It’s not a donation, it’s an investment. IFFIm has been so successful, it has changed the face of global development funding.
A partnership that puts children first
IFFIm’s unique financing model for global health is built upon partnerships. IFFIm receives long term, legally binding pledges from donor countries and, with the World Bank acting as Treasury Manager, turns these pledges into bonds. The money raised via Vaccine Bonds provides immediate funding for Gavi, the Vaccine Alliance. Since, 2000 Gavi has dramatically improved access to new and underused vaccines for children living in the world’s poorest countries.
Accelerating funding for life-saving vaccines
IFFIm accelerates the delivery of vaccines by making the money from long term government donor pledges available immediately. Through this funding mechanism, known as “frontloading,” IFFIm has helped Gavi to immunise more children sooner and has made vaccines more widely available.
By creating a larger market and by stimulating greater competition from manufacturers, Gavi has played a major role in driving down the cost of vaccines for low-income countries since 2000.
Vaccine Bonds supporting Gavi
Vaccine Bonds speed the availability of flexible funds for Gavi’s immunisation programmes and other initiatives on the ground, including unexpected emergencies. This saves more lives faster. Vaccine Bonds also lead to funding that is more predictable, enabling public health officials to plan vaccination campaigns well in advance. Forward planning strengthens local health systems and translates into healthier populations overall, a crucial building block for a successful economy.
Vaccines are one of the best buys in health. Each dollar of investment in immunisation will give a return of 21 dollars, rising to 54 dollars when broader societal benefits are included.
IFFIm’s financing model puts donor pledges to work faster
IFFIm's financing model puts donor pledges to work faster. For example: a sovereign donor pledges US$ 200 million paid in US$10 million tranches annually over 20 years. Without IFFIm, Gavi would be limited to spending only this US$10 million each year and would have to wait 20 years before seeing its full impact.
But backed by these pledges, IFFIm issues its Vaccine Bonds on the international capital markets. Capital market investors buy these bonds for an attractive rate of return, which makes funds immediately available to IFFIm
Gavi uses the proceeds of these bond issuances to purchase more vaccines to immunise more children in the world’s poorest countries.
In order to ensure investors of its ability to pay back interest and principal, IFFIm only raises bonds against a percentage of their overall pledge. IFFIm uses the remainder as a reserve to make sure that there will always be more than sufficient funds to pay bondholders when the bonds mature.
Donors’ annual payments to IFFIm—or proceeds from new bond issues—go toward repayment to bondholders. For example, with a 5-year bond, at the end of 5 years, IFFIm would have paid interest, and will return full principal to the investors.
At the end of the donor payment period and after all bonds are redeemed, IFFIm can transfer to Gavi any outstanding reserve—that was earlier set aside-to purchase more vaccines.
Awards and recognition
IFFIm Vaccine Bond issuance named "Deal of the Year" by mtn-i
2019
Cited as “SRI Innovation of the Decade” by mtn-i, the news / analytics provider
2013
IFFIm’s debut Sukuk was awarded Social Impact Deal of 2014 by Islamic Finance News
The UK's Foreign, Commonwealth and Development Office awarded IFFIm an A+ rating for effectiveness, efficiency and economy
2023
Restricted Access Library
The material in this Restricted Access Library is intended to be accessed only by persons with residence within the territory of a Member State of the European Union and is not intended to be viewed by any other persons. The material in this Restricted Access Library is provided by IFFIm for information purposes only and the materials contained herein were accurate only as of their respective dates. Certain information in the materials contained herein is not intended to be, and is not, current. IFFIm accepts no obligation to update any material contained herein.
Persons with residence outside the territory of a Member State of the European Union who have access to or consult any materials posted in this Restricted Access Library should refrain from any action in respect of the securities referred to in such materials and are otherwise required to comply with all applicable laws and regulations in their country of residence.
By clicking Access restricted content: DYNAMIC-LINK-TEXT I confirm that I have read and understood the foregoing and agree that I will be bound by the restrictions and conditions set forth on this page.
The materials in this Restricted Access Library are for distribution only to persons who are not a "retail client" within the meaning of section 761G of the Corporations Act 2001 of Australia and are also sophisticated investors, professional investors or other investors in respect of whom disclosure is not required under Part 6D.2 of the Corporations Act 2001 of Australia and, in all cases, in such circumstances as may be permitted by applicable law in any jurisdiction in which an investor may be located.
The materials in this Restricted Access Library and any documents linked from it are not for access or distribution in any jurisdiction where such access or distribution would be illegal. All of the securities referred to in this Restricted Access Library and in the linked documents have been sold and delivered. The information contained herein and therein does not constitute an offer for sale in the United States or in any other country. The securities described herein and therein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable state securities laws.
Each person accessing the Restricted Access Library confirms that they are a person who is entitled to do so under all applicable laws, regulations and directives in all applicable jurisdictions. Neither IFFIm nor any of their directors, employees, agents or advisers accepts any liability whatsoever for any loss (including, without limitation, any liability arising from any fault or negligence on the part of IFFIm or its respective directors, employees, agents or advisers) arising from access to Restricted Access Library by any person not entitled to do so.